MedX Health Corporation's Profile

The company has commercialized a highly effective skin cancer scanning device. Patients can receive their prognosis and receive treatment within 72 hours after the initial screening. Initial orders from its Brazilian distribution partner could result in $8M of hardware sales over the next 2 years.
MedX Health Corporation
Symbol
MDX
Exchange
TSX-V
Shares
175,961,524 as of 03/31/2021
Industry
Technology & Medical
Website
Create a Post

Top Members

TREASURER
Last Posted:
08/09/2021
Rating:
Messages:
104
ADMINISTRATOR
Last Posted:
06/17/2021
Rating:
Messages:
143
MAIL ROOM
Last Posted:
11/18/2020
Rating:
Messages:
5
MAIL ROOM
Last Posted:
10/03/2020
Rating:
Messages:
2

MedX Health Corporation's Bulletin

MedX Health Corp. (“MedX” or the “Company”) (MDX: TSX-V) announced its results for the three and six-months ended June 30, 2021, which are also available on SEDAR ( www.sedar.com ). The Company reported revenue of $146,532 for the three-months ended June 30, 2021, compared with revenue of $69,452 for the three-months ended June 30, 2020. Revenues from the Company’s SIAscopy ® /DermSecure ® products were lower than in 2020, while sales for the therapeutic laser product line was three times the revenue from the 2020 second quarter. The Company reported a loss for the three-months ended June 30, 2021, of $1,234,836, or $0.01 per share compared with a loss of $708,212, or $0.00 per share for the three-months ended June 30, 2020. The Company reported revenue of $256,189 for the six-months ended June 30, 2021, compared with revenue of $164,996 for the six-months ended June 30, 2020. Revenues from the Company’s SIAscopy ® /DermSecure ® products increased 19% from the 2020 six-month period, and sales for the therapeutic laser product line were 73% higher than the prior year. The Company reported a loss for the six-months ended June 30, 2021, of $2,267,178, or $0.01 per share compared with a loss of $1,448,396, or $0.01 per share for the six-months ended June 30, 2020. “We have begun generating revenue from scanning by customers using our SIAscopy ® /DermSecure ® telemedicine platform after the launch in the Netherlands earlier in the year, and expect increasing activity,” noted Sylvain Desjeans, the recently appointed President and CEO of MedX. “From my initial work to date, I see a number of opportunities where our efforts should result in an increasing number of units sold, and more importantly, the recurring revenue from DermSecure ® . We have made good progress in the integration of a high-definition camera onto DermSecure ® , which will further enhance our offering, and will be ready to launch before the end of the year. The broadened offering will provide a multiple to the potential revenue growth with the focus now on teledermatology.” About MedX MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy ® on DermSecure ® telemedicine platform, utilizing its SIAscopy ® technology. SIAscopy ® is also imbedded in SIAMETRICS ® , a well-regarded research system used to assess treatment effectiveness of a variety of skin conditions, including burns. The Company’s SIAscope ® and other devices are manufactured in its ISO 13485 certified facility. The SIAscope ® is a hand-held device that uses patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with the Company’s software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. DermSecure ® meets all privacy, security and relevant regulatory requirements in Canada, the US, Brazil, and the EU. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com. Forward-looking Statements This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005844/en/ Bill Mitoulas, Investor RelationsMedX Health Corp+1.416.479.9547bill@medxhealth.com Source: Business Wire (August 24, 2021 - 6:00 PM EDT)News by QuoteMediawww.quotemedia.com
MedX Health Corp. (“MedX” or the “Company”) ( MDX – TSXV), announces that at the Annual and Special General Meeting of shareholders held on August 16, 2021, Rob von der Porten retired as a director, thus creating a vacancy on the Board. Mr. von der Porten had been not only Chairman of the Board, but also acting as Chief Executive Officer during the last fifteen-month period that MedX was conducting a search for a new CEO. Ken McKay has been appointed as Chairman of the Board. In addition, Sylvain Desjeans, recently promoted to President and CEO of MedX, has been appointed to the Board to fill the vacancy created by the retirement of Mr. von der Porten. “The Board thanks Rob for his service and leadership during a period of over seven years, during which time the Company has developed into being a leading medical device and software company. During his tenure, MedX completed the development of its SIAscopy™ on DermSecure TM Telemedicine platform.” stated Mr. McKay “I am proud to have worked with my MedX colleagues who are so committed to the development of the SIAscopy™ technology and the DermSecure TM Telemedicine platform,” said Mr. von der Porten. “It represents a significant leap forward for early detection of skin cancers as well as the assessment of other skin conditions with the addition of its high-definition camera. I am confident that the Company will leverage its technology across North America and internationally to achieve great commercial success” he continued. About MedX MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com . Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. View source version on businesswire.com:https://www.businesswire.com/news/home/20210823005667/en/ Bill Mitoulas, Investor Relations MedX Health Corp +1.416.479.9547 bill@medxhealth.com   Source: Business Wire (August 23, 2021 - 7:00 PM EDT) 
Health-care industry leader poised to accelerate the Company’s global growth plans MedX Health Corporation (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that Sylvain Desjeans has been appointed as the Company’s President and Chief Executive Officer, effective immediately. With more than 30 years of health-care and pharmaceutical industry experience, Mr. Desjeans served in successively senior roles at organizations such as Aspen Pharmacare Canada, Accucaps Industries Limited and Biovail Pharmaceuticals. He has a long track record of successfully executing large-scale growth plans and global product licensing initiatives. Mr. Desjeans joined MedX on May 5, 2021, as Chief Revenue Officer, and has been working on the Company’s market opportunities, including the application of the MedX Dermsecure® platform’s artificial intelligence features, as well as initiatives focussed on revenue generation. His appointment follows a comprehensive recruitment process led by the MedX Board of Directors. “Sylvain brings extensive knowledge of, and experience in, the global medical technology market,” said Rob von der Porten, Chairman of the MedX Board of Directors. “As a leader, he is exceptional at building sales, opening distribution channels and developing high-performing teams that deliver results, all of which are imperative for MedX to achieve our growth plans in Canada, the US and internationally.” Sylvain Desjeans stated, “I am honoured at this appointment, and I look forward to helping MedX realize its potential during a time of substantial growth for the Company. We’ve learned from the challenges of the COVID-19 pandemic that there is a strong need for increasing access and speed to healthcare for patients. I’m energized by the fact that our products are uniquely positioned to maintain a leadership position in this industry. Ultimately, our purpose at MedX is to save lives.” MedX’s leading telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image-capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy® is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface. Teledermatology, is a subspecialty of dermatology that offers safe and effective virtual patient assessment and diagnosis at a distance, eliminating the need for in-person appointments. As the world continues to navigate through ongoing COVID-19 recovery measures, teledermatology's advancement has never been more critical to patient care and outcomes. About MedX: MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com . Forward Looking Statements: This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.  
Leading Teledermatology Screening Platform to Immediately Be Offered in More Clinics Across Ontario; North American Expansion in The Coming Months MedX Health Corporation (“MedX” or the “Company”) (TSX-V: MDX) a global leader in teledermatology, is pleased to announce a distribution agreement with VidaCeuticals Health Products Inc. that will see MedX’s integrated skin assessment teledermatology platform offered at four clinics in Ontario beginning in late June, with plans for a broader market roll-out in Canada and the United States later this year. The initial four clinics will be located in London, Ottawa, Port Elgin and Sarnia. “With only about 500 dermatologists available to serve over 37 million Canadians, the wait times to see a dermatologist in-person can be anywhere from five months to one year,” said Sylvain Desjeans, MedX’s Chief Revenue Officer. “The COVID-19 pandemic has nearly doubled the average wait period. We know that early detection of melanoma greatly increases the patient’s survival rate and reduces the cost to the health-care system. Increasing accessibility to scanning through partnering with VidaCeuticals and their deep network of clinic partners will help us work towards early skin cancer detection.” Alignment on company values and a passion to save lives drew VidaCeuticals Health Products Inc. to connect with MedX to support a strategic and aggressive distribution plan to reach more North Americans with MedX’s technology – its SIAscope™ imaging device and DermSecure™ cloud-based telemedicine platform. “We have shared values and a passion for finding solutions that are easy to access and that ultimately improve and save lives, avoiding unnecessary health impacts on families and communities,” explained Jean-Guy Bourguignon, Managing Director of VidaCeuticals Health Products Inc. “VidaCeuticals is looking forward to growing with MedX to expand across Canada and the United States with the mission of increasing access to skin screening and lesion assessment thereby improving patient outcomes.” According to the Canadian Dermatology Association, last year an estimated 8,000 Canadians were diagnosed with melanoma skin cancer and approximately 1,300 Canadians died of the disease. With mortality rates increasing by as much as 1.2% per year since 1984, early and rapid detection is key to improving patient outcomes. About MedX MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, a well-regarded research system used to assess treatment effectiveness of a variety of skin conditions, including burns. The Company’s SIAscope™ and other devices are manufactured in its ISO 13485 certified facility. The SIAscope™ is a hand-held device that uses patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. DermSecure™ meets all privacy, security and relevant regulatory requirements in Canada, the US, Brazil, and the EU. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com About VidaCeuticals Health Products VidaCeuticals Health Products Inc. focuses on connecting people with innovative health solutions, with a focus on distributing proprietary and innovative product lines and devices, helping people to achieve longevity through a healthier quality of life as naturally as possible. Visit: www.VidaCeuticals.com This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. View source version on businesswire.com: https://www.businesswire.com/news/home/20210615006182/en/ Investors and Media: Bill Mitoulas MedX Health Corp. bill@medxhealth.com 416-479-9547 Jean-Guy Bourguignon VidaCeuticals Health Products Inc. Jean-Guy@VidaCeuticals.com 800-641-6024 Ext 1